Catalent's Clinical Trial Supply Facility in Shanghai, China Opens for Business
![](/46/pdcnewsitem/03/27/91/g5KKFi9NwuNXfVG.png)
Catalent Pharma Solutions, the global leader in development solutions and advanced delivery technologies for drug, biologic and consumer health products, has announced that construction and validation of its Clinical Supply facility in Shanghai, China has been completed. Catalent business leaders, local employees, customers and partners celebrated at a site opening ceremony on 8 November 2013, less than 9 months after construction began on the site.
It is the first clinical supply facility in China to provide end-to-end clinical supply solutions from clinical supply management, comparator sourcing and primary packaging to storage and distribution. The facility is also validated to support biologics requiring refrigerated and frozen supply chain management. Catalent has already secured customer projects for the site, which is now undergoing customer validation for the supply of clinical trial materials.
Catalent currently supports the clinical trial supply needs of the top 25 pharmaceutical companies and more than 300 small innovators from all over the world. The new, state-of-the-art, 31,000 sq ft facility has been constructed to the company’s proven ‘center of excellence’ guidelines and will operate to Catalent’s global Quality Management System. The Catalent (Shanghai) Clinical Trial Supplies Co., Ltd facility is the eighth in Catalent’s global clinical supply network and is located in Shanghai’s Waigaoqiao Free Trade Zone.
“China is a fast growing market for the pharmaceutical industry and a market that Catalent will continue to invest in,” commented Scott Houlton, President of Development and Clinical Services at Catalent. “Having started work on our China clinical supply strategy 2 years ago, I’m excited to see this strategy implemented and the new site open for business. It is a great addition to Catalent’s global clinical supply network and will help to better serve our customers increasing need for clinical trials in Asia.”
Dr Weiyan “Jackson” Zhu, Catalent's Country General Manager for China added: “The recently appointed local management team brings a huge combined prior experience of clinical trials management, pharmaceuticals and healthcare. Together with Catalent’s GMP facility in Singapore, the company is well positioned to serve the clinical trials needs of our regional and global customers.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance